DENG Yuli
Mathematics and Statistics, Year 3

Department of Statistics and Actuarial Science,
Simon Fraser University, Canada

A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). 

The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV. It also offers a new strategy by increasing the uptake of anti-cancer drugs in tumour cells, thus allowing the application of lower drug dosages which helps reduce treatment side effects and health risks. 

EBV is one of the most common viruses in humans, having infected more than 90% of the human population worldwide. It is widely known that the virus plays a key role in several cancers such as nasopharyngeal carcinoma (NPC), which is highly prevalent in Hong Kong and southern China.

Led by Professor Gary Wong Ka-Leung, Professor and Head of the Department of Chemistry at HKBU, Dr Lung Hong Lok, Assistant Professor of the Department of Chemistry at HKBU, and Dr Law Ga-lai, Associate Professor of the Department of Applied Biology and Chemical Technology at The Hong Kong Polytechnic University, the research team constructed a novel drug with a peptide, i.e., a component of the building blocks of various proteins, that can target two EBV-specific viral proteins – Latent membrane protein 1 (LMP1) and Epstein–Barr nuclear antigen 1 (EBNA1). They are the viral proteins which are expressed in all EBV-infected tumour cells, and both play a vital role in the development and progression of EBV-associated tumours.

Leveraging the success of the first-generation drugs developed by the research team in recent years, this novel dual-targeting drug employs the treatment mechanisms of: (1) targeting and binding to EBNA1, making it no longer functional, and (2) inhibiting LMP1 and serving as an imaging agent. Since LMP1 is more accessible to drug targeting due to its presence on the surface of cells, the ability of the new drug to selectively identify EBV-infected cancer cells is largely enhanced.


DENG Yuli
Mathematics and Statistics, Year 3

A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). 

The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV. It also offers a new strategy by increasing the uptake of anti-cancer drugs in tumour cells, thus allowing the application of lower drug dosages which helps reduce treatment side effects and health risks. 

EBV is one of the most common viruses in humans, having infected more than 90% of the human population worldwide. It is widely known that the virus plays a key role in several cancers such as nasopharyngeal carcinoma (NPC), which is highly prevalent in Hong Kong and southern China.

Led by Professor Gary Wong Ka-Leung, Professor and Head of the Department of Chemistry at HKBU, Dr Lung Hong Lok, Assistant Professor of the Department of Chemistry at HKBU, and Dr Law Ga-lai, Associate Professor of the Department of Applied Biology and Chemical Technology at The Hong Kong Polytechnic University, the research team constructed a novel drug with a peptide, i.e., a component of the building blocks of various proteins, that can target two EBV-specific viral proteins – Latent membrane protein 1 (LMP1) and Epstein–Barr nuclear antigen 1 (EBNA1). They are the viral proteins which are expressed in all EBV-infected tumour cells, and both play a vital role in the development and progression of EBV-associated tumours.

Leveraging the success of the first-generation drugs developed by the research team in recent years, this novel dual-targeting drug employs the treatment mechanisms of: (1) targeting and binding to EBNA1, making it no longer functional, and (2) inhibiting LMP1 and serving as an imaging agent. Since LMP1 is more accessible to drug targeting due to its presence on the surface of cells, the ability of the new drug to selectively identify EBV-infected cancer cells is largely enhanced.

Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Lorem ipsum dolor sit amet, consectetur adipisicing elit.

DENG Yuli
Mathematics and Statistics, Year 3

The IAPR/IEEE Winter School on Biometrics 2021 (WSB2021) was held in Shenzhen on 24-28 January, 2021. Jointly organized by the Department of Computer Science, Hong Kong Baptist University, the Institute of Automation, Chinese Academy of Sciences and the Department of Computer Science and Engineering, Southern University of Science and Technology, the winter school attracted around 90 participants, including professors and senior postgraduate students from world-wide tertiary institutions. Due to the worldwide outspread of COVID-19, the winter school introduced online lecture as well.

The 5-day winter school included lectures, hands-on session, talks from industry and social programme. To consolidate the fundamental knowledge of biometrics and share the latest biometric development, the scope of the course is designed to cover the topics which mainly include mobile biometrics, anti-spoofing, template protection, and fundamental of different biometric modalities. New and challenging topics are covered in the course by internationally renowned experts from all over the world.

The IAPR/IEEE Winter School on Biometrics 2021 (WSB2021) was held in Shenzhen on 24-28 January, 2021. Jointly organized by the Department of Computer Science, Hong Kong Baptist University, the Institute of Automation, Chinese Academy of Sciences and the Department of Computer Science and Engineering, Southern University of Science and Technology, the winter school attracted around 90 participants, including professors and senior postgraduate students from world-wide tertiary institutions. Due to the worldwide outspread of COVID-19, the winter school introduced online lecture as well.

The 5-day winter school included lectures, hands-on session, talks from industry and social programme. To consolidate the fundamental knowledge of biometrics and share the latest biometric development, the scope of the course is designed to cover the topics which mainly include mobile biometrics, anti-spoofing, template protection, and fundamental of different biometric modalities. New and challenging topics are covered in the course by internationally renowned experts from all over the world.

The 5-day winter school included lectures, hands-on session, talks from industry and social programme.

Copyright © 2021 All rights reserved